ADVA
16.11.2021 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s playing a key role in three research projects focused on significantly increasing the capacity of optical networks by using space division multiplexing (SDM) technology. Partly funded by Germany’s Federal Ministry of Education and Research (BMBF), the initiatives aim to transform optical transport systems by utilizing several parallel transmission paths. The research will focus on new ways to tackle the exponential rise in data traffic while continuing to reduce cost per bit. Running for three years, the projects will develop and demonstrate solutions to enable the next generation of high-performance networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005052/en/
“With new data-intensive applications such as automated driving, smart cities and IoT services, a paradigm shift is needed in the architecture of backbone networks. Annual growth rates in internet traffic are predicted to exceed 25%. That means digital infrastructure will have to handle three times as much traffic every five years and a hundred times as much in just two decades. Our role in these projects will help to massively increase network capacity in an economical and energy-efficient way,” said Christoph Glingener, CTO, ADVA. “SDM technology will be key to tomorrow’s transport infrastructure. By combining time, frequency and space division multiplexing, we can tackle the bottlenecks that are already emerging and support the digital transformation of our society.”
The projects feature a consortium of industry and research partners working to harness the potential of space multiplexing in fiber optic networks. That requires solving challenges and developing novel solutions in several key technology areas. These include a new generation of terminals to light up large chunks of capacity in a “rack-and-stack” fashion, optical switching nodes and amplifiers tailored to handle a large number of parallel signal paths, as well as disruptive innovation on new fibers. ADVA is leading the “Scalable terminal architectures and subsystems for fiber optic space multiplexing (STARFALL)” project, aimed at highly-integrated terminals for data center interconnects, as well as the “Wavelength selective switches for optical space multiplex (WESORAM)” project focused on novel optical switch architectures. ADVA’s team will also play a central role in the “Multi-core fibers and amplifiers with the highest capacity (Multi-Cap)” project, which will advance fiber transmission and optical amplification for SDM applications.
“These partner initiatives are a crucial step in confronting the mobile data crunch and enabling the continued digitalization of all areas of our lives. The solutions we’re developing here will empower operators to keep pace with enormous traffic growth while facilitating autonomous, zero-touch operations,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “SDM techniques will be fundamental to the next stage in the evolution of the data landscape. They provide an opportunity to sidestep the Shannon Limit and ensure our networks won’t be outstripped by the pace of innovation in other areas. Once again, our team is at the forefront, leading the way towards scalable and sustainable optical networks of the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005052/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
